Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Aljosja Rogiers, Florentia Dimitriou, Irene Lobón, Catriona Harvey, Ismael A. Vergara, Inês Pires da Silva, Serigne Lo, Richard A Scolyer, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

Article

Discussion(0)

No comments yet. Be the first to comment.

Publication Info

DOI: 10.1038/s41422-018-0031-9
Year: 2018
Published: —
Language: en

Letter Details

Volume: 28
Issue: 5
Link Of The Paper: https://doi.org/10.1038/s41422-018-0031-9

Timeline

Created:June 19, 2026

2020

Intestinal microbiota predict response and toxicities during anti-PD-1/anti-CTLA-4 immunotherapy

Rebecca Simpson, Marcel Batten, Erin R. Shanahan, Mark Read, Inês Pires da Silva, Alexandra Aangelatos, Jian Tan, Chandra Mani Adhikari, Jordan W. Conway, Alex Menzies, Jonathan R. Stretch, Omgo E. Nieweg, Andrew J. Spillane, Laurence Macia, Maria Gonzales, Kerwin F. Shannon, Rebecca Velickovic, Christian U. Blank, Andrew Holmes, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Editorial Material2019

Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma

Masatoshi Kudo

Editorial Material2019

Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies

Masatoshi Kudo

Article2017

Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.

Tuba N. Gide, Camelia Quek, Jason Madore, Alexander M. Menzies, Rebecca Dent, Matteo S. Carlino, Alex Guminski, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Richard A Scolyer, Georgina V. Long